News
Tirzepatide is more effective than semaglutide for weight loss, according to a new study on GLP-1 medications ; The study was ...
10h
Adweek on MSNGLP-1 Weight Loss Drugs are Disrupting Brands. The Vitamin Shoppe Is the Latest Chasing the UpsideAnd since GLP-1s come with side effects including fatigue, digestive difficulties, and loss of muscle, products to address ...
Adult patients taking Wegovy saw a reduced risk of experiencing a major adverse cardiovascular event within the first three months of treatment, according to a secondary analysis of the drug’s ...
20h
News-Medical.Net on MSNGLP-1 weight loss drugs leave users low on key nutrients, study findsThis study assessed nutrient intake in adults using GLP-1 receptor agonists (GLP-1RAs) and found widespread deficiencies in ...
New research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May) and published in the ...
Glucagon-like peptide-1 (GLP-1) receptor agonists are gaining popularity as a weight loss solution due to their effectiveness in managing appetite and blood sugar levels. We spoke with Dr ...
With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...
GLP-1 Weight Loss Drugs Cut Alcohol Cravings By Two-Thirds By Dennis Thompson HealthDay ReporterTUESDAY, May 13, 2025 (HealthDay News) — Cutting-edge weight-loss drugs like Ozempic/Wegovy can ...
As GLP-1 firms continue to bulk up, WeightWatchers (WW) is stepping off the scale. The points-system-based weight loss program filed for bankruptcy on May 6, with its premarket value plummeting 52 ...
This comprehensive review explores MEDVi, a leading telehealth provider offering compounded GLP-1 weight loss solutions like Semaglutide and Tirzepatide in both injection and tablet form.
Patients reported that cutting back on alcohol was effortless, researchers said TUESDAY, May 13, 2025 (HealthDay News) — Cutting-edge weight-loss drugs ... like peptide-1 (GLP-1) drugs mimic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results